Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
InflaRx ( (IFRX) ) has issued an announcement.
On November 10, 2025, InflaRx announced positive topline results from its Phase 2a study of INF904 in treating HS and CSU. The study demonstrated rapid and clinically meaningful improvements in patients, with no serious adverse events reported. These results highlight INF904’s potential as a transformative treatment in these conditions, supporting further development into Phase 2b trials. The company is actively engaging with potential collaborators to expedite development and capitalize on the growing interest in the C5aR mechanism.
The most recent analyst rating on (IFRX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
InflaRx’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and cash flow challenges. Technical analysis provides a slightly more neutral outlook, but valuation concerns due to a negative P/E ratio further weigh down the score. The absence of earnings call insights and corporate events leaves these areas unaddressed.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V. is a biopharmaceutical company based in Jena, Germany, specializing in anti-inflammatory therapeutics that target the complement system. The company is focused on developing its orally administered small-molecule C5aR inhibitor, INF904, for treating conditions such as hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).
Average Trading Volume: 1,082,007
Technical Sentiment Signal: Sell
Current Market Cap: $82.57M
Find detailed analytics on IFRX stock on TipRanks’ Stock Analysis page.